LYELLyell Immunopharma, Inc.vs its industry peers
A metric-by-metric comparison of Lyell Immunopharma, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LYELThis | $275M#7 | — | 1.2x#1 | 7644.2x#5 | -41.0%#4 | 20.0%#2 | -748344.4%#5 | -117.4%#4 | — | — | -31.8%#1 | — |
| TTRX | $302M#1 | — | 440.0x#5 | — | — | -80.6%#6 | — | -465.0%#5 | — | — | — | — |
| IRD | $301M#2 | — | — | 21.2x#3 | 29.1%#1 | 13.8%#4 | -271.9%#3 | — | — | — | — | — |
| VOGX | $293M#3 | — | — | — | — | — | — | — | — | — | — | — |
| BNTC | $293M#4 | — | 1.7x#3 | — | -100.0%#6 | -20.6%#5 | — | -25.8%#2 | — | — | — | — |
| CYPH | $281M#5 | 4.1x#1 | 2.0x#4 | 187.5x#4 | 0.0%#3 | 107.4%#1 | -2737.8%#4 | 3.6%#1 | — | — | — | — |
| ARCT | $281M#6 | — | 1.6x#2 | 3.4x#2 | -46.1%#5 | 18.7%#3 | -93.0%#2 | -38.3%#3 | -136.2%#2 | — | — | — |
| LFCR | $243M#8 | — | — | 1.9x#1 | 0.5%#2 | -422.5%#7 | -13.4%#1 | — | -28.7%#1 | 3#1 | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice